Design of a Phase 2 Clinical Trial of an ASK1 Inhibitor, GS-4997, in Patients with Diabetic Kidney Disease | Zendy

Joseph H. Lin | Zendy; Jenny J. Zhang | Zendy; ShaoLee Lin | Zendy; Glenn M. Chertow | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Design of a Phase 2 Clinical Trial of an ASK1 Inhibitor, GS-4997, in Patients with Diabetic Kidney Disease

Author(s) -

Joseph H. Lin,

Jenny J. Zhang,

ShaoLee Lin,

Glenn M. Chertow

Publication year - 2014

Publication title -

the nephron journals/nephron journals

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.951

H-Index - 72

eISSN - 2235-3186

pISSN - 1660-8151

DOI - 10.1159/000369152

Subject(s) - medicine , albuminuria , clinical endpoint , renal function , kidney disease , diabetic nephropathy , population , oxidative stress , clinical trial , oncology , kidney , environmental health

Most patients with diabetic kidney disease (DKD) experience disease progression despite receiving standard care therapy. Oxidative stress is associated with DKD severity and risk of progression, but currently approved therapies do not directly attenuate the pathologic consequences of oxidative stress. GS-4997 is a once daily, oral molecule that inhibits Apoptosis Signal-regulating Kinase 1 (ASK1), which is a key mediator of the deleterious effects of oxidative stress.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research